Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism. The novel oral compound, FOR-6219, is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. The first women participating in the study have been dosed.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH